文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌预后生物标志物:生物学基础与证据

Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.
PubMed 文献 · BJU Int · 2026-10-11

本文综述非肌层浸润性膀胱癌(NMIBC)的预后和治疗反应生物标志物,关注其生物学功能、标本类型、检测方法、统计证据及可能的临床应用。文献聚焦2015年1月至2026年8月的英文人体研究,优先纳入报告复发、进展、生存或膀胱内治疗反应的NMIBC队列。多数证据来自回顾性单队列研究,效应值和截断值不一致,且少有标志物能实质改善临床病理模型。结论是目前尚无生物标志物可替代指南推荐的风险分层或膀胱镜监测。

要点

  • 肿瘤组织标志物如STAG2、FGFR3、FAP-α等与染色体稳定性、生长因子信号、基质重塑和上皮间质转化相关。
  • 尿液RNA和血浆循环肿瘤DNA可实现无创采样,但结果依赖标本处理和检测条件。
  • 血源性炎症指标便宜但非特异;多数证据来自回顾性单队列研究,标志物尚不能替代指南风险分层。

核心结论

  • 目前综述涉及的生物标志物均不能替代指南推荐的风险分层或膀胱镜监测。

研究设计与样本

  • 聚焦性叙述性检索PubMed、Web of Science和Cochrane Library,纳入2015年1月至2026年8月发表的英文人体研究,并补充早期关键研究和参考文献筛选。
  • 优先纳入报告复发、进展、生存或膀胱内治疗反应的NMIBC队列,考虑队列特异性、样本量、多变量分析、独立人群验证和检测标准化。

主要发现

  • 肿瘤组织标志物如STAG2、FGFR3、成纤维细胞激活蛋白-α、尿激酶纤溶酶原激活物系统和钙黏蛋白与染色体稳定性、生长因子信号、基质重塑、细胞外基质侵袭和上皮间质转化相关。
  • 尿液RNA和血浆循环肿瘤DNA允许无创采样,但结果依赖标本处理和检测条件。
  • 血源性炎症指标便宜但非特异;多数证据来自回顾性单队列研究,报告的效应值和截断值不一致,且少有标志物能实质改善临床病理模型。

临床怎么用

  • 临床暂不应以综述中的生物标志物替代指南风险分层或膀胱镜监测。
  • 未来研究应前瞻性定义检测方法和阈值,在独立队列中验证,并证明添加标志物能以可接受成本改善预测和患者管理。

局限性

  • 多数证据来自回顾性单队列研究,效应值和截断值不一致。
  • 少有标志物能实质改善临床病理模型。
  • 尿液RNA和血浆循环肿瘤DNA的结果依赖标本处理和检测条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review prognostic and treatment-response biomarkers for non-muscle-invasive bladder cancer (NMIBC), with particular attention to biological function, specimen type, assay method, statistical evidence, and possible clinical use. METHODS: We conducted a focused narrative search of PubMed, Web of Science, and the Cochrane Library for English-language human studies published from January 2015 to August 2026, supplemented by earlier pivotal studies and reference-list screening. Priority was given to NMIBC cohorts reporting recurrence, progression, survival, or response to intravesical therapy. We considered cohort specificity, sample size, multivariable analysis, testing in an independent population, and assay standardisation. RESULTS: Tumour-tissue markers such as stromal antigen 2 (STAG2), fibroblast growth factor receptor 3 (FGFR3), fibroblast activation protein-α, the urokinase plasminogen activator system, and cadherins are linked to chromosomal stability, growth-factor signalling, stromal remodelling, extracellular-matrix invasion, and epithelial-mesenchymal transition. Urinary RNAs and plasma circulating tumour DNA permit non-invasive sampling, although results depend on specimen handling and assay conditions. Blood-derived inflammatory indices are inexpensive but non-specific. Most evidence comes from retrospective single-cohort studies; reported effects and cut-offs are not always consistent, and few markers materially improve clinicopathological models. CONCLUSIONS: None of the biomarkers reviewed can currently replace guideline-based risk stratification or cystoscopic surveillance. Future studies should define assays and thresholds prospectively, test them in independent cohorts, and show that adding a biomarker improves prediction and patient management at an acceptable cost.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhao Y, Ye Y, et al. Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence. BJU Int. 2026. PMID: 42860325. doi:10.1111/bju.70488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。